rokitamycin and Gingivitis

rokitamycin has been researched along with Gingivitis* in 1 studies

Trials

1 trial(s) available for rokitamycin and Gingivitis

Article	Year
[Clinical studies on TMS-19-Q.O tablets, the preparation of a new macrolide antibiotic, in the field of oral surgery]. The Japanese journal of antibiotics, 1985, Volume: 38, Issue:3 Multicenter clinical trial or TMS-19-Q.O tablet was performed to evaluate the usefulness in oral surgery. The results obtained were as follows: Clinical efficacy was assessed by clinical points. The patients entered into the trial were 77 cases with periodontitis, 23 with pericoronitis, 92 with osteitis of jaw and 18 with other infections, and the each effective rates were 80.5, 60.9, 83.7 and 72.2%, respectively. Overall effective rate was 79.0%. Isolation frequency of organisms were 33.8% in periodontitis, 34.8% in osteitis of jaw and 17.4% in pericoronitis. Bacteria isolated were aerobic organisms (63.1%) and anaerobic organisms (36.9%). TMS-19-Q.O tablet was well tolerated, and no adverse reaction was observed. Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clinical Trials as Topic; Female; Gingivitis; Humans; Jaw Diseases; Leucomycins; Male; Microbial Sensitivity Tests; Middle Aged; Miocamycin; Periodontitis; Streptococcus pyogenes; Tablets	1985

Article

Year

[Clinical studies on TMS-19-Q.O tablets, the preparation of a new macrolide antibiotic, in the field of oral surgery].

The Japanese journal of antibiotics, 1985, Volume: 38, Issue:3

Multicenter clinical trial or TMS-19-Q.O tablet was performed to evaluate the usefulness in oral surgery. The results obtained were as follows: Clinical efficacy was assessed by clinical points. The patients entered into the trial were 77 cases with periodontitis, 23 with pericoronitis, 92 with osteitis of jaw and 18 with other infections, and the each effective rates were 80.5, 60.9, 83.7 and 72.2%, respectively. Overall effective rate was 79.0%. Isolation frequency of organisms were 33.8% in periodontitis, 34.8% in osteitis of jaw and 17.4% in pericoronitis. Bacteria isolated were aerobic organisms (63.1%) and anaerobic organisms (36.9%). TMS-19-Q.O tablet was well tolerated, and no adverse reaction was observed.

Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clinical Trials as Topic; Female; Gingivitis; Humans; Jaw Diseases; Leucomycins; Male; Microbial Sensitivity Tests; Middle Aged; Miocamycin; Periodontitis; Streptococcus pyogenes; Tablets

1985